SAN MATEO, Calif. & SHANGHAI–(BUSINESS WIRE)–Terns Pharmaceuticals Inc., a global biopharmaceutical company focused
on discovering and developing molecularly targeted, oral, small-molecule
drugs to treat NASH and cancer, today announced that Randy Halcomb,
Ph.D., senior vice president of chemistry and early development, will
present a corporate overview and update on the Company’s lead programs
at BioCentury’s 26th Annual Future Leaders in the Biotech Industry
Conference on Friday, April 12, 2018 at 2pm Eastern Time in room
404/405. The conference is being held at the Millennium Broadway Hotel
in New York City.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company
that is focused on the discovery and development of medicines for
chronic liver disease and cancer. Based in China and the United States,
the company is advancing a pipeline of small molecule drug candidates
for the treatment of non-alcoholic steatohepatitis (NASH) and cancer,
across multiple modalities. Terns leverages world class expertise in
disease biology, medicinal chemistry, and clinical development, in order
to bring promising new therapies to patients in China and other global
markets.
For more information, visit www.ternspharma.com
and www.ternspharma.com.cn.
Contacts
US Media Contact:
Margaret Robinson
(415) 690-0084
China Media Contact:
Xia Zou
+86 18523948668